CD8A and neoplasm: With biologically and therapeutically relevant initialization conditions for both phenotype and T cell ratio, we ran simulations with 1% CD8+ T cells (12 T cells to 1,200 tumor cells) to compare our two differentially activated T cell phenotypes (with 2HC: 25% PD-1+; without 2HC: 75% PD-1+) as separate therapies over a period of 72 h.